Single-Cell Circulating Tumor Cell Analysis Reveals Genomic Instability as a Distinctive Feature of Aggressive Prostate Cancer

Abstract

Purpose: Aggressive variant prostate cancer (AVPC) represents a clinical subset distinguished by therapy resistance and poor prognosis, linked to combined losses of the tumor suppressor genes (TSG) PTEN, RB1, and TP53. Circulating tumor cells (CTC) provide a minimally invasive opportunity for identification and molecular characterization of AVPC. We aimed to evaluate the incidence and clinical significance of compound (2þ)TSG losses and genomic instability in prostate cancer CTC, and to expand the set genomic biomarkers relevant to AVPC.Experimental Design: Genomic analysis of chromosomal copy-number alterations (CNA) at single-cell resolution was performed in CTC from patients with and without AVPC before initiating chemotherapy with cabazitaxel or cabazitaxel and carboplatin. We evaluated associations between single-CTC genomics and clinical features, progression-free survival, and overall survival.Results: A total of 257 individual CTC were sequenced from 47 patients (1-22 CTC/patient). Twenty patients (42.6%) had concurrent 2þTSG losses in at least one CTC in association with poor survival and increased genomic instability, inferred by high large-scale transitions scores. Higher LST in CTC were independent of CTC enumerated, clinically more indicative of aggressive behavior than co-occurring TSG losses, and molecularly associated with gains in chromosomal regions including PTK2, Myc, and NCOA2; increased androgen receptor expression; and BRCA2 loss. In 57 patients with matched cell-free tumor DNA data, CTC were more frequently detectable and evaluable for CNA analysis (in 73.7% vs. 42.1%, respectively).Conclusions: Our findings suggest that genomic instability in CTC is a hallmark of advanced prostate cancer aggressiveness, and support single-CTC sequencing as a compelling tool to noninvasively characterize cancer heterogeneity.

Development and Interpretation of a Genomic Instability Derived lncRNAs Based Risk Signature as a Predictor of Prognosis for Clear Cell Renal Cell Carcinoma Patients

“…GI is a major cause of tumor heterogeneity within and between tumors (5). Moreover, it is broadly recognized that GI is closely related with the progression and prognosis of tumors (6)(7)(8)(9).…”

Tumor Evolution and Therapeutic Choice Seen through a Prism of Circulating Tumor Cell Genomic Instability

“…Additional CNA profiling studies in CRPC highlight high levels of genomic heterogeneity among CTCs [59,60]. The compound losses of three tumor suppressors (PTEN, RB1 and TP53) in PCa CTCs and the corresponding circulating tumor DNA analysis were recently reported and linked to the aggressive trait of the tumor [61]. Moreover, gains in PTK2 and MYC together with TP53 loss were also detected in CTCs and were strongly associated with poor prognosis in PCa patients.…”

Metastatic Spread in Prostate Cancer Patients Influencing Radiotherapy Response

“…determined copy-number alteration in 257 isolated CTCs from 47 patients with aggressive PCa treated with cabazitaxel- and carboplatin-based chemotherapy and found a higher frequency of detectable chromosomal alteration in CTCs compared to match-paired cell-free tumor DNA (73.7% vs. 42.1%). The observed genomic instability in CTCs is independent of the CTC count and associated with chromosomal gains in regions containing the PTK2 , MYC , and NCOA2 gene increased AR expression, and BRCA2 loss ( 217 ). This opens new preclinical and clinical questions:…”